Nature Medicine, Published online: 30 June 2026; doi:10.1038/s41591-026-04449-9
In the phase 1 ReMIND trial of tumor-associated antigen-specific T cells in patients with pediatric central nervous system tumors, treatment was generally well tolerated with one complete response and three long-term responders.